Oyen J.,University of Bergen |
Gjesdal C.G.,University of Bergen |
Brudvik C.,University of Bergen |
Hove L.M.,University of Bergen |
And 4 more authors.
Osteoporosis International | Year: 2010
Summary: One third of 218 men and half of 1,576 women with low-energy distal radius fractures met the bone mineral density (BMD) criteria for osteoporosis treatment. A large proportion of patients with increased fracture risk did not have osteoporosis. Thus, all distal radius fracture patients ≥50 years should be referred to bone densitometry. Introduction Main objectives were to determine the prevalence of patients with a low-energy distal radius fracture in need of osteoporosis treatment according to existing guidelines using T-score ≤ -2.0 or ≤-2.5 standard deviation (SD) and calculate their fracture risk. Methods: A total of 218 men and 1,576 women ≥50 years were included. BMD was assessed by dual energy X-ray absorptiometry (DXA) at femoral neck, total hip, and lumbar spine (L2-L4). The WHO fracture risk assessment tool (FRAX®) was applied to calculate the 10-year fracture risk. Results T-scores ≤-2.0 and ≤-2.5 SD at femoral neck was found in 37.7% and 19.6% of men and 51.1% and 31.2% of women, respectively. The risk of hip fracture was 6.2% for men and 9.0% for women. The corresponding figures for patients with T-score ≤-2.0 SD were 11.6% and 14.5% and for T-score ≤-2.5 SD 16.3% and 18.2%, respectively. A large proportion of distal radius fracture patients with a high 10-year FRAX® risk did not have osteoporosis. Conclusions: Every second to every third fracture patient met the present BMD criteria for osteoporosis treatment. Because a large proportion of distal radius fracture patients did not have osteoporosis, treatment decisions should not be based on fracture risk assessment without bone densitometry. Thus, all distal radius fracture patients ≥50 years should be referred to bone densitometry, and if indicated, offered medical treatment. © International Osteoporosis Foundation and National Osteoporosis Foundation 2009.
Zangi H.,National Resource Center for Rehabilitation in Rheumatology |
Mowinckel P.,National Resource Center for Rehabilitation in Rheumatology |
Finset A.,University of Oslo |
Eriksson L.R.,Diakonhjemmet Hospital |
And 3 more authors.
Annals of the Rheumatic Diseases | Year: 2012
Objective: To evaluate the effects of a mindfulnessbased group intervention, the Vitality Training Programme (VTP), in adults with inflammatory rheumatic joint diseases. Methods: In a randomised controlled trial, the VTP-a 10-session mindfulness-based group intervention including a booster session after 6 months-was compared with a control group that received routine care plus a CD for voluntary use with mindfulnessbased home exercises. The primary outcome was psychological distress measured by the General Health Questionnaire-20. Self-efficacy (pain and symptoms) and emotion-focused coping (emotional processing and expression) were used as co-primary outcomes. Secondary outcomes included pain, fatigue, patient global disease activity, self-care ability and well-being. Effects were estimated by mixed models repeated measures post-intervention and at 12-month follow-up. Results: Of 73 participants randomised, 68 completed assessments post-intervention and 67 at 12 months. Significant treatment effects in favour of the VTP group were found post-treatment and maintained at 12 months in psychological distress (adjusted mean between-group difference -3.7, 95% CI -6.3 to -1.1), self-efficacy pain (9.1, 95% CI 3.4 to 14.8) and symptoms (13.1, 95% CI 6.7 to 19.3), emotional processing (0.3, 95% CI 0.02 to 0.5), fatigue (-1.1, 95% CI -1.8 to -0.4), self-care ability (1.0, 95% CI 0.5 to 1.6) and overall well-being (0.6, 95% CI 0.1 to 1.2). No significant group differences were found in emotional expression, pain or disease activity. Conclusion: The VTP improved most primary and secondary outcomes compared with individual use of CD exercises. Improvements were maintained at 12 months, suggesting that the VTP is a beneficial complement to existing treatments for patients with inflammatory rheumatic joint diseases.
Dobloug G.C.,University of Oslo |
Antal E.A.,OUH |
Sveberg L.,OUH |
Garen T.,University of Oslo |
And 5 more authors.
European Journal of Neurology | Year: 2015
Background and purpose: Knowledge about the occurrence of sporadic inclusion body myositis (sIBM) in the general population is limited. Here, our aim was to identify and characterize every sIBM patient living in southeast Norway (population 2.64 million) from 2003 to 2012. Method: Two sIBM case finding strategies were applied. First, all hospital databases in southeast Norway were screened to identify cases with sIBM-compatible International Classification of Diseases 10 (ICD-10) codes. These cases were then manually chart reviewed. Secondly, all muscle histology reports encoded with inflammation were independently reviewed. Finally, cases were classified according to the 1997 and the 2011 European Neuro-Muscular Centre (ENMC) Research Diagnostic Criteria for sIBM. Results: The combined case finding strategy identified 3160 patients with sIBM compatible ICD-10 codes, and a largely overlapping cohort of 500 patients having muscle biopsies encoded with inflammation. Detailed retrospective review of chart and histology data showed that 95 patients met the 2011 ENMC sIBM criteria and 92 met the 1997 criteria. Estimated point prevalence of sIBM was 33/1 000 000, equal with both criteria sets. Mean age at diagnosis was 66.9 years and mean diagnostic delay was 5.6 years. Chart review revealed higher frequencies of dysphagia (94% vs. 65%) and anti-Sjøgren syndrome A antibodies (39% vs. 12%) in female sIBM patients (n = 40) than in males. Coexisting rheumatic diseases were present in 25% of sIBM cases, with Sjøgren's syndrome in 10%. Conclusion: An estimated point prevalence of sIBM seven times higher than previously observed in Europe is reported. Our data show considerable diagnostic delay, a major challenge with new sIBM treatments in the pipeline. © 2014 EAN.
Van Leeuwen J.A.M.J.,Betanien Hospital |
Grogaard B.,University of Oslo |
Nordsletten L.,University of Oslo |
Rohrl S.M.,University of Oslo
Acta Orthopaedica | Year: 2015
Background and purpose - Intraoperatively, patient-specific positioning guides (PSPGs) represent the preoperatively planned alignment. We investigated the degree of correlation between preoperative planning and the alignment achieved postoperatively with the PSPG technique. Patients and methods - TKAs performed with the PSPG technique between 2009 and 2011 were included. 39 patients (42 TKAs) volunteered for a postoperative CT scan. 2 independent observers performed the postoperative CT measurements. Preoperative component angles (target angles) in the coronal and axial planes were defined as 0 degrees, and in the sagittal plane on average 2.8 degrees for the femoral component and 3 degrees for the tibial component. A postoperative full-length standing anteroposterior radiograph was carried out in 41 TKAs. Results - The femoral component was on average 1.2 (SD 1.5) degrees in varus, 4.4 (SD 4.0) degrees in flexion, and 0.5 (SD 1.4) degrees in external rotation. The tibial component was on average 0.4 (SD 2.5) degrees in varus and 3.7 (SD 2.3) degrees in flexion. A statistically significant difference between the target (preoperative software plan) and postoperative CT measurement was found for the femoral component angle in the frontal plane (p < 0.001; CI: 0.8-1.7), the sagittal plane (p = 0.01; CI -5.6 to -3.1), and the axial plane (p = 0.03; CI: 0.04-0.88). HKA angles were greater than 3 degrees from the neutral axis in 10 of the 41 cases. Interpretation - We found our postoperative component alignment angles to be close to the software plan, especially for the tibial component. However, we found outliers in all planes and we cannot therefore conclude that the PSPG technique is a method that reproduces preoperatively planned alignment in a consistent manner. Copyright © 2014 Nordic Orthopaedic Federation.
Kass A.,University of Oslo |
Hollan I.,Lillehammer Hospital for Rheumatic Diseases |
Fagerland M.W.,University of Oslo |
Gulseth H.C.,Betanien Hospital |
And 2 more authors.
PLoS ONE | Year: 2015
Objectives: Gonadotropin-releasing hormone (GnRH) and pituitary gonadotropins, which appear to be proinflammatory, undergo profound secretory changes during events associated with rheumatoid arthritis (RA) onset, flares, or improvement e.g. menopausal transition, postpartum, or pregnancy. Potential anti-inflammatory effects of GnRH-antagonists may be most pronounced in patients with high GnRH and gonadotropin levels. Therefore, we investigated the efficacy and safety of a GnRH-antagonist, cetrorelix, in RA patients with high gonadotropin levels. Methods: We report intention-to-treat post hoc analyses among patients with high gonadotropin levels (N = 53), i.e. gonadotropin levels>median, from our proof-of-concept, double-blind AGRAstudy (N = 99). Patients with active longstanding RA, randomized to subcutaneous cetrorelix (5mg days1-2; 3mg days 3-5) or placebo, were followed through day 15. Only predefined primary and secondary endpoints were analyzed. Results: The primary endpoint, Disease Activity Score of 28-joint counts with C-reactive protein (DAS28-CRP), improved with cetrorelix compared with placebo by day 5 (-1.0 vs. -0.4, P = 0≥010). By day 5, more patients on cetrorelix achieved at least a 20% improvement in the American College of Rheumatology scale (44% vs. 19%, P = 0.049), DAS28-CRP≤3.2 (24% vs. 0%, P = 0.012), and European League against Rheumatism 'Good-responses' (19% vs. 0%, P = 0.026). Tumor necrosis factor-α, interleukin-1β, interleukin-10, and CRP decreased with cetrorelix (P = 0.045, P = 0.034, P = 0.020 and P = 0.042 respectively) compared with placebo by day 15. Adverse event rates were similar between groups. Conclusions: GnRH-antagonism produced rapid anti-inflammatory effects in RA patients with high gonadotropin levels. GnRH should be investigated further in RA. Copyright: © 2015 Kåss et al This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.